Abstract: A technique is provided for improving the stability of a halogenated isoquinoline derivative with respect to light in an aqueous composition. A pharmaceutical preparation obtained by storing an aqueous composition comprising a compound represented by Formula (1): wherein X represents a halogen atom, or a salt thereof, or a solvate of the compound or the salt thereof, in a package that blocks a ray with a wavelength of 300 to 335 nm.

Abstract: Compositions for a viscous topical anesthetic for use in in-office treatments or surgical procedures are described. The compositions comprise a mixture of two anesthetic agents incorporated into a positively charged nanoparticle and suspended in a viscosifying solution. The described compositions increase the dispersion and absorption of the anesthetics.

Abstract: Provided herein are dried compositions and methods for preparing such compositions for use in delivery of a nucleic acid to a subject. The dried composition may comprise a lipid carrier, wherein the lipid carrier is a nanoemulsion comprising a hydrophobic core, optionally one or more inorganic nanoparticles and one or more lipids, one or more nucleic acid, and at least one cryoprotectant. Methods of using these dried compositions for treatment are also provided.

Abstract: Various embodiments of a metered dose inhaler are disclosed. The inhaler includes a metering valve, a canister, and an actuator having an actuator nozzle. The canister includes a formulation having greater than 70% by weight of HFO-1234ze(E), and at least one active pharmaceutical ingredient suspended in the formulation to form a suspension.

Abstract: Nucleic acid immunisation is achieved by delivering RNA encapsulated within a PEGylated liposome. The RNA encodes an immunogen of interest. The PEG has an average molecular mass of between 1 kDa and 3 kDa. Thus the invention provides a liposome having a lipid bilayer encapsulating an aqueous core, wherein: (i) the lipid bilayer campuses at least one lipid which includes a polyethylene glycol moiety, such that polyethylene glycol is present on the liposome's exterior, wherein the average molecular mass of the polyethylene glycol is between 1 kDa and 3 kDa; and (ii) the aqueous core includes a RNA which encodes an immunogen. These liposomes are suitable for in vivo delivery of the RNA to a vertebrate cell and so they are useful as components in pharmaceutical compositions for immunising subjects against various diseases.

Abstract: The present invention relates to a pharmaceutical composition comprising a weak acid drug, with the use of a bicarbonate salt to achieve a high incorporation of the drug into the liposome and a better therapeutic efficacy. Also disclosed is a method for treating a respiratory disease using the pharmaceutical composition disclosed herein.

Abstract: The disclosure presented herein provides methods for producing a dispersion of nanoparticles, as for example liposomes, by a method comprising frontally colliding an organic stream with an aqueous stream at raised pressure.

Abstract: The invention pertains to a method for treating a neoplasm, such as colorectal cancer, using hollow silica spheres (“HSS”).

Abstract: Microsphere formulations comprising nalmefene are provided. In one aspect, the microsphere formulations are characterized in that the nalmefene is released over a period of about 60 days or more. Methods for making and using the microsphere formulations are also provided.

Abstract: A manufacturing method of medication includes the following steps. Firstly, an effective dosage of an API is dissolved in a dissolved agent to form a first solution, wherein the API includes triamcinolone acetonide or YC-1 compound. Next, the first solution is filtered through a filter membrane at a room temperature to obtain a second solution. Then, a precipitating agent is added into the second solution to obtain a third solution, followed by continuously stirring the third solution to precipitate crystals. The third solution is further stirred under the room temperature, a low pressure to sequentially remove the dissolved agent and the precipitating agent.

Abstract: The present invention relates to sustained release tablet comprising micronized tolcapone, a release retardant and a binder, to said tablet for use in the prevention and/or treatment of a transthyretin-associated amyloidosis, to a method for the prevention and/or treatment of a transthyretin-associated amyloidosis comprising administering to a subject in need thereof an effective amount of said tablet, to pharmaceutical composition in the form of said tablet which is used in the prevention and/or treatment of a transthyretin-associated amyloidosis and to a process for the manufacture of said tablet.

Abstract: Packaged formulations of gamma-hydroxybutyrate having improved dissolution and chemical stability after storage for up to at least 72 months, packaging for supporting said stability, and therapeutic uses thereof.

Abstract: Alpelisib Formulation The invention features a granular formulation comprising an internal phase consisting of free flowing granules including alpelisib, or a pharmaceutically acceptable salt thereof, as active pharmaceutical ingredient and at least one pharmaceutically acceptable carrier material, and preferably in addition an external phase without said API comprising at least one pharmaceutically acceptable carrier material; and related invention embodiments.

Abstract: In an embodiment, the present disclosure pertains to a nanocarrier having a shell and a core disposed within the shell. In some embodiments, the shell includes a functionalized surface. In an additional embodiment, the present disclosure pertains to a method of drug delivery. In general, the method includes administering a nanocarrier to a subject, targeting, by the nanocarrier, an area in the subject, and releasing a composition having the drug to the area. In some embodiments, the nanocarrier has a shell and a core disposed within the shell. In some embodiments, the shell includes a functionalized surface.

Abstract: A nanosphere includes a metal oxide hollow nanosphere and a poly-L-histidine. The metal oxide is selected from the group consisting of cerium(IV) oxide (CeO2), aluminum oxide (Al2O3), copper(II) oxide (CuO), titanium dioxide (TiO2), sodium oxide (Na2O), zinc oxide (ZnO), gold(II) oxide (AuO), iron(II, III) oxide (Fe3O4), and combinations thereof. The poly-L-histidine is grafted on a surface of the metal oxide hollow nanosphere. A drug delivery carrier including the nanosphere, and a method for alleviating an anterior segment eye disease using the drug delivery carrier are also disclosed.

Abstract: Compositions, processes, and methods are provided including, but not limited to, a composition including a plurality of clay nanoparticles, wherein each clay nanoparticle comprises an anionic component and a cationic component wherein the anionic component has the formula (I): wherein 5.5<b?6, and wherein c>0 and b/c>12.

Abstract: This disclosure relates to ionizable amino lipid-based lipid nanoparticles for delivery of mRNA encoding propionyl-CoA carboxylase alpha (PCCA) and propionyl-CoA carboxylase beta (PCCB). Lipid nanoparticle/mRNA therapies of the invention increase and/or restore deficient levels of PCCA and/or PCCB expression and/or activity in subjects and are useful for the treatment of propionic academia.

Abstract: Disclosed are lipidoid compositions that are capable of treating or preventing certain diseases (e.g., cancer or viral infections). Also disclosed are pharmaceutical compositions, comprising the lipidoid compositions. The disclosure also relates to methods of using the lipidoid compositions, and related kits comprising the lipidoid compositions.

Abstract: Provided are methods for delivering lipid nanoparticles (LNPs) to a lung cell of a subject suffering from or at risk for primary ciliary dyskinesia (PCD), wherein the method comprises nebulizing a liquid pharmaceutical composition to generate an aerosolized pharmaceutical composition, and administering the aerosolized pharmaceutical composition to the subject.

Abstract: Herein disclosed are nanoparticles comprising a phospholipid, apolipoprotein and/or an apolipoprotein mimetic, sterol, cationic lipid or ionizable cationic lipid and a nucleic acid and compositions comprising such nanoparticles and a method for preparing such nanoparticles. The nanoparticles may be used as a medicament, such as in the treatment of a disease by stimulating or inhibiting an innate immune response.

Abstract: The present invention relates to trans-epithelial membrane delivery systems, methods and kits that include an agent to penetrate the basement membrane, a membrane of the skin and mucosa previously known to be difficult to penetrate. In particular, the formulation includes a basement membrane disruptor that reversibly denatures or cleaves molecules of the basement membrane of the epithelial membrane. The formulation of the present invention further includes having at least one penetration agent, at least one vaso-modulator, and at least one active ingredient. In an embodiment, the penetration agent includes a solvent, a lipophilic agent, a hydrophilic agent, wherein the basement membrane disruptor, the vaso-modulator, and the active ingredient pass through the outer layers of the epithelial membrane. The basement membrane disruptor allows the vaso-modulator and the active ingredient pass through the basement membrane to smooth muscle.

Abstract: The present application presents compositions and methods for the intranasal administration of perillyl alcohol and L-Dopa to a patient in need of treatment for Parkinson's Disease.

Abstract: The present invention relates to the use of propanediol mononitrate in combination with certain natural substances for reducing the production of methane emanating from the digestive activities of said ruminant as well as in increasing the organic matter digestibility in said ruminant.

Abstract: The present invention discloses a system and method for preparing and delivering various precursor compositions as a replacement therapy for testosterone and other hormone deficiencies that naturally occur with aging in humans and other mammals. Precursor compositions are selected and designed for the purpose of formulating non-toxic therapeutic hormone supplement for oral consumption. The invention features low dose continuous supplementation to be incorporated with daily meals. The process of the present invention delivers an orally ingested substance, e.g., a food, supplement, etc., that contains an anti-aging formulation comprising a hormone precursor (prohormone) that is absorbed by the digestive system and secreted into the bloodstream with a second substance to facilitate its ingestion, absorption and delivery to the body's tissues.

Abstract: Compositions and tri-molecular complexes of polyphenol-polysaccharide-protein are provided wherein the polyphenol is non-covalently complexed with covalently-linked polysaccharide and protein. The bioavailability of the polyphenol is such compositions is significantly increased in the disclosed compositions and tri-molecular complexes. Such compositions may be used to deliver high concentrations of the polyphenol for treating various conditions and diseases.

Abstract: In order to make available the health-promoting and healing properties of curcumin to the human or animal organism, also in combination with at least one further active substance, a solubilizate consists of or contains a content of curcumin equal to or smaller than 10 wt %, preferably equal to or smaller than 7.5 wt %, most preferably 6 wt %, and at least one emulsifier with an HLB value in a range below 18, preferably between 13 and 18, namely polysorbate 80 or polysorbate 20 or a mixture of polysorbate 20 and polysorbate 80, with an average diameter of the curcumin-loaded micelles ranging from 5 nm to 40 nm, preferably from 6 nm to 20 nm, most preferably from 7 nm to 10 nm, for use in particular as a dietary supplement and/or pharmaceutical drug for treating and/or preventing diseases involving inflammation, cancer and other diseases.

Abstract: A topical composition for treating genital herpes includes dimethyl sulfoxide (DMSO), a diluent, and a quaternary ammonium compound. The topical composition may further contain a cannabinoid component, such as CBD, and/or a terpene and/or an essential oil. The topical composition may be in the form of a two-component composition in which a first topical composition includes dimethyl sulfoxide (DMSO), a diluent, and a quaternary ammonium compound and the second topical composition includes dimethyl sulfoxide (DMSO), a diluent, and a cannabinoid component.

Abstract: The present invention relates to transmucosal therapeutic systems for the transmucosal administration of agomelatine comprising a mucoadhesive layer structure comprising a therapeutically effective amount of agomelatine, such agomelatine transmucosal therapeutic systems for use in a method of treatment, a method of treatment comprising applying such agomelatine transmucosal therapeutic systems, and processes of manufacture of such transmucosal therapeutic systems.

Abstract: Provided herein according to some embodiments is a method for decreasing the potential for adverse events from solriamfetol in an infant fed breast milk obtained from a subject treated with solriamfetol comprising: orally administering the solriamfetol to the subject at a daily dose of about 37.5 mg to about 300 mg; and feeding the infant breast milk from the subject at least about 5 hours after administering the solriamfetol to the subject, thereby decreasing potential for adverse events from solriamfetol in an infant.

Abstract: Provided herein according to some embodiments is a method for decreasing the potential for adverse events from solriamfetol in an infant fed breast milk obtained from a subject treated with solriamfetol comprising: orally administering the solriamfetol to the subject at a daily dose of about 37.5 mg to about 300 mg; and feeding the infant breast milk from the subject at least about 5 hours after administering the solriamfetol to the subject, thereby decreasing potential for adverse events from solriamfetol in an infant.

Abstract: Provided herein according to some embodiments is a method for decreasing the potential for adverse events from solriamfetol in an infant fed breast milk obtained from a subject treated with solriamfetol comprising: orally administering the solriamfetol to the subject at a daily dose of about 37.5 mg to about 300 mg; and feeding the infant breast milk from the subject at least about 5 hours after administering the solriamfetol to the subject, thereby decreasing potential for adverse events from solriamfetol in an infant.

Abstract: Provided herein according to some embodiments is a method for decreasing the potential for adverse events from solriamfetol in an infant fed breast milk obtained from a subject treated with solriamfetol comprising: orally administering the solriamfetol to the subject at a daily dose of about 37.5 mg to about 300 mg; and feeding the infant breast milk from the subject at least about 5 hours after administering the solriamfetol to the subject, thereby decreasing potential for adverse events from solriamfetol in an infant.

Abstract: Provided herein are combinations of capsaicin and TrpV1 modulators that are useful for treating capsaicin-responsive diseases or disorders.

Abstract: The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC0-tau less than 400 ng·h/mL, (ii) a Cmax no more than 40 ng/ml, or (iii) both.

Abstract: The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC0-tau less than 400 ng·h/mL, (ii) a Cmax no more than 40 ng/ml, or (iii) both.

Abstract: The present disclosure relates to dispersible pharmaceutical compositions comprising N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, and, optionally, a pharmaceutically acceptable carrier.

Abstract: The present invention relates to methods and sets of drugs for the effective treatment of metastatic cancer and the administration of a set of drugs that overcome mechanisms of resistance to DNA-damaging agents, thereby sensitizing cancer cells to said DNA-damaging agents. The methods involve the administration of a set of drugs comprising melphalan, BCNU, hydroxocobalamin, and ascorbic acid. In a preferred embodiment, ethanol is also added to the set of drugs and bone marrow toxicity is reversed with an infusion of bone marrow stem cells. The methods also involve the depletion of GSH in tumors and the selective delivery of drugs to solid tumors. The methods also involve preventing the loss of catalase function and preventing oxidant-induced hemolysis and/or methemoglobin formation in subjects treated with oxidant drugs or agents that generate hydrogen peroxide, wherein said methods comprise the systemic administration of ethanol.

Abstract: The present technology is related to reducing or treating neurological swelling and related conditions with SUR1-TRPM4 channel inhibitors. In some embodiments, the methods include: reducing late neurological deterioration or preventing death, reducing cerebral midline shift, reducing the degree of disability in a subject, counteracting blood glucose levels in a subject receiving a SUR1-TRPM4 channel inhibitor, preventing brain swelling, monitoring liver enzyme activity along with treating injury or conditions related to CNS edema, or monitoring cardiac activity along with treating injury or conditions related to CNS edema.

Abstract: The claimed uses of bioidentical free D-BetaHydroxyButyric Acid as a method (1303), system (1411) and optional co-adjuvant compound for pharmaceutical co-administration with Psilocybin compounds to treat Depression, Anxiety and Bipolar Disorder are novel, safe and not anticipated by the body of research spanning well over 75 years. Overall, no adverse findings have been reported within cell, animal and human safety studies at high dose levels with D-BetaHydroxyButyric acid which supports the safety and efficacy of the claimed uses at the anticipated usage levels for the disclosed applications.

Abstract: A fully dilutable in aqueous phase self-microemulsifying system for the delivery of one or more polar oil active compounds having a positive characteristic curvature (Cc), comprising: a lecithin compound; a hydrophilic linker or a combination two or more hydrophilic linkers, the hydrophilic linker or the combination of two or more hydrophilic linkers having one having one hydrocarbon group with 6 to 10 carbon atoms, and the hydrophilic linker or the combination of two or more HLs having a Cc of about ?5 or more negative than about ?5; and a carrier oil.

Abstract: The invention relates to compounds for use in the treatment of liver failure.

Abstract: The invention relates to compounds for use in the treatment of sepsis.

Abstract: The invention relates generally to the field of medical treatment. More particularly, the invention relates to treating a patient in order to increase the amount of ketones metabolized by mitochondria. Exemplary patients include those with Alzheimer's disease and insulin resistance.

Abstract: The invention provides methods, compositions, and kits containing a first therapeutic agent that is a substituted 2,3-dimethoxyquinone of Formula I, or a pharmaceutically acceptable salt thereof, for treating patients suffering from diabetic retinopathy, diabetic macular edema, and/or other diabetic retinal disorders and/or other disorders.

Abstract: Methods are provided that relate to the discovery that dihomo-gamma linolenic acid (DGLA) is a potent senolytic agent. Accordingly, in certain embodiments, methods of selectively killing one or more senescent cells in a subject in need thereof are provided wherein the method(s) involves administering to the subject an effective amount of DGLA.

Abstract: A method for treating inflammatory bowel disease includes administering to a subject in need thereof a composition comprising a compound represented by Chemical Formula 1 or a pharmaceutically or sitologically acceptable salt thereof. The compound represented by Chemical formula 1 not only can suppress the inflammatory responses by inhibiting the phosphorylation activity of RIPK2 and exhibits an effect of regenerating intestinal mucus layer in accordance with recovery of the tight junction-related proteins as an intercellular junction factor but also has an effect of reducing the transcription amount of proinflammatory cytokine mRNA in zebra fish animal model of inflammatory bowel disease. Thus, it can be advantageously used for a pharmaceutical product, a functional health food product, or an animal feed for preventing, ameliorating, or treating inflammatory bowel disease.

Abstract: Described herein is a novel two-component composition including acetylsalicylic acid (ASA) and which is particularly useful in providing an aqueous solution of ASA for immediate peroral administration such as to treat imminent myocardial infarction in a person in need thereof.

Abstract: Antitumor pharmaceutical compositions and methods of treatment for a variety of cancers, in which the antitumor compositions can be used alone or in combination with existing cancer therapies. The antitumor compositions can comprise or consist essentially of a combination of methyl jasmonate, cis-jasmone, and d-limonene. In a further aspect, the antitumor compositions can comprise or consist essentially of any two of methyl jasmonate, cis-jasmone, and d-limonene. Carriers or adjuvants such as squalene can be used with the compositions. This combination of components provides unexpected benefits, including synergistic enhancements cancer treatment and pain management when used with existing cancer therapies.

Abstract: It has been found that the prodrug 1-(butyryloxy)ethyl-5-amino-4-oxopentanoate (AN-233), an oral active conjugate of BA (histone deacetylase inhibitor) and ALA (heme precursor), is useful for the treatment of hemoglobinopathies including but not limited to sickle cell disease and thalassemias. In one embodiment, AN-233 activates ?-globin transcription, induces HbF expression, produces an anti-sickling effect, or combinations thereof when administered to a subject in need thereof.

Abstract: Compositions of matter suitable for use in food, feed, pharmaceutical, and beauty care products comprising a retinoid component and a fermentative residue thereof are disclosed herein. In an embodiment, the retinoid component is present in a ratio by weight relative to the fermentative residue of 4:1 or greater, wherein the retinoid contains cis- and trans-isomers, wherein the cis-isomers are present by weight relative to the entire mixture of isomers in an amount less than 3 wt. %. Preferably, the compositions are bio-based. Also described are biotechnological methods of producing the compositions elsewhere described, along with further methods for processing such compositions into more stabilized, more commercially acceptable forms. Finally, also disclosed are food, feed, pharmaceutical, and beauty care products incorporating the compositions herein described.